Abbott Laboratories (NYSE: ABT) on Thursday reported mixed results for the first quarter of fiscal 2026, with sales beating analysts’ consensus estimates and earnings matching the Street view.
First-quarter sales increased 7.8% to $11.16 billion from $10.36 billion in the year-ago quarter, exceeding estimates. The top line grew 3.7% on a comparable basis.
Earnings, on an adjusted basis, increased 6% to $1.15 per share in Q1 from $1.09 per share in the comparable period of fiscal 2025. The latest number is in line with expectations. On a reported basis, net income dropped to $1.08 billion or $0.61 per share in Q1 from $1.33 billion or $0.76 per share in Q1 FY25.
Management projects full-year 2026 comparable sales growth of 6.5-7.5%1. It forecasts FY26 adjusted earnings in the range of $5.38 per share to $5.58 per share.
“Our first-quarter results were aligned with our expectations to start the year. The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year,” said Robert Ford, CEO of Abbott.
The post Abbott (ABT) Q1 FY26 earnings match estimates; sales beat first appeared on Alphastreet.
